Jan 09, 2023 / 07:15PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
Great. Good morning, everyone. My name is Jess Fye. I'm the large-cap biotech analyst at JPMorgan, and we're delighted to be continuing the conference today with Intra-Cellular. So good news is you don't have to switch rooms for Q&A. I'm going to rerunning the Q&A session at the end of Sharon's presentation. If you want to submit a question to the portal, I got an iPad up here, you can just shoot it over to me, and I will ask it. So with that, let me turn it over to Intra-Cellular CEO, Sharon Mates.
Sharon Mates - Intra-Cellular Therapies, Inc. - Co-Founder, Chairman, CEO & President
Thank you, Jessica. It's a pleasure to be here today. I'm joined here today with our Chief Commercial Officer, Mark Neumann; and our SVP and Head of Clinical Development, Willie Earley. And during the Q&A, they'll come up here and be on the podium to answer any questions.
So before I start, my presentation today contains forward-looking statements within the meaning of the Private
Intra-Cellular Therapies Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers